These findings have important implications for mechanisms of ubiquitin activation during normal and pathophysiological processes and lay the foundation for developing novel therapeutic strategies for VEXAS syndrome and other UBA1-related diseases in the future. This evidence concerns the gene UBC and VEXAS syndrome.